Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly
The Lancet Oncology,  Clinical Article

Wick W et al. – Temozolomide alone is non–inferior to radiotherapy alone in the treatment of elderly patients with malignant astrocytoma. MGMT promoter methylation seems to be a useful biomarker for outcomes by treatment and could aid decision–making.

Methods
  • Between May 15, 2005, and Nov 2, 2009, the authors enrolled patients with confirmed anaplastic astrocytoma or glioblastoma, age older than 65years, and a Karnofsky performance score of 60 or higher.
  • Patients were randomly assigned 100mg/m2 temozolomide, given on days 1-7 of 1week on, 1week off cycles, or radiotherapy of 60.0Gy, administered over 6-7weeks in 30 fractions of 1.8-2.0Gy.
  • The primary endpoint was overall survival.
  • They assessed non-inferiority with a 25% margin, analysed for all patients who received at least one dose of assigned treatment.

Results
  • Of 584 patients screened, the authors enrolled 412.
  • 373 patients (195 randomly allocated to the temozolomide group and 178 to the radiotherapy group) received at least one dose of treatment and were included in efficacy analyses.
  • Median overall survival was 8.6months (95% CI 7.3-10.2) in the temozolomide group versus 9.6months (8.2-10.8) in the radiotherapy group (hazard ratio [HR] 1.09, 95% CI 0.84-1.42, pnon-inferiority=0.033).
  • Median event-free survival (EFS) did not differ significantly between the temozolomide and radiotherapy groups (3.3months [95% CI 3.2-4.1] vs 4.7 [4.2-5.2]; HR 1.15, 95% CI 0.92-1.43, pnon-inferiority=0.043).
  • Tumour MGMT promoter methylation was seen in 73 (35%) of 209 patients tested.
  • MGMT promoter methylation was associated with longer overall survival than was unmethylated status (11.9months [95% CI 9.0 to not reached] vs 8.2months [7.0-10.0]; HR 0.62, 95% CI 0.42-0.91, p=0.014).
  • EFS was longer in patients with MGMT promoter methylation who received temozolomide than in those who underwent radiotherapy (8.4months [95e% CI 5.5—11.7] vs 4.6 [4.2—5.0]), whereas the opposite was true for patients with no methylation of the MGMT promoter (3.3 months [3.0-3.5] vs 4.6months [3.7-6.3]).
  • The most frequent grade 3-4 intervention-related adverse events were neutropenia (16 patients in the temozolomide group vs two in the radiotherapy group), lymphocytopenia (46 vs one), thrombocytopenia (14 vs four), raised liver-enzyme concentrations (30 vs 16), infections (35 vs 23), and thromboembolic events (24 vs eight).

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Nursing

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Nursing Articles

1 Yogurt consumption, weight change and risk of overweight/obesity: The SUN cohort study Nutrition, Metabolism & Cardiovascular Diseases, July 28, 2014    Clinical Article

2 Vitamin D and sleep disorders Full Text Nature and Science of Sleep, August 13, 2014    Free full text    Clinical Article

3 Blood pressure in relation to coffee and caffeine consumption Current Hypertension Reports, August 8, 2014    Review Article

4 Metformin in chronic kidney disease: Time for a rethink Peritoneal Dialysis International, July 9, 2014    Clinical Article

5 Suffering from constipation? Self-acupressure can help UCLA Health System, November 19, 2014

6 Effect of ginger (Zingiber officinale) on heavy menstrual bleeding: a placebo-controlled, randomized clinical trial Phytotherapy Research, October 13, 2014    Clinical Article

7 UAB plans clinical trial for repurposed drug shown to reverse diabetes UAB Medicine, November 12, 2014

8 Long-term associations of nut consumption with body weight and obesity American Journal of Clinical Nutrition, June 23, 2014    Clinical Article

9 Decreased ability to identify odors can predict death The University of Chicago Medical Center News, October 3, 2014

10 Chocolate intake and diabetes risk Clinical Nutrition, July 21, 2014    Clinical Article

11 Vitamin D and the risk of dementia and Alzheimer's disease Neurology®, August 27, 2014    Clinical Article

12 Vitamin D and melanoma and non-melanoma skin cancer risk and prognosis: A comprehensive review and meta-analysis European Journal of Cancer, August 7, 2014    Review Article

13 Study identifies best way to treat neck pain Johns Hopkins Medicine, October 24, 2014

14 Yogurt and weight management American Journal of Clinical Nutrition, April 3, 2014    Review Article

15 Proton pump inhibitors decrease diversity in gut microbiome, increase risk for complications Mayo Clinic, November 25, 2014

16 'Tis the season to indulge in walnuts UC Davis Health System, November 17, 2014

17 Fish consumption and risk of gastrointestinal cancers: A meta-analysis of cohort studies Full Text World Journal of Gastroenterology, November 17, 2014    Free full text    Evidence Based Medicine

18 Associations of sugar and artificially sweetened soda and chronic kidney disease: A systematic review and meta-analysis Nephrology, September 24, 2014    Evidence Based Medicine    Review Article

19 Eating habits, body fat related to differences in brain chemistry Full Text NIH News, September 10, 2014    Free full text

20 Dairy product consumption and gastric cancer risk: A meta-analysis Full Text World Journal of Gastroenterology, November 14, 2014    Free full text    Evidence Based Medicine

Indexed Journals in Nursing: Journal of Advanced Nursing, Journal of Clinical Nursing, Nurse Education In Practicemore